Details of the Drug Pharmacogenomic Perturbation Atlas

Cladribine Drug Info

Chlorodeoxyadenosine; Cladarabine; Cladaribine; Cladribina; Cladribinum; CldAdo; Leustat; Leustatin; Litak; Movectro;Mylinax; CL9; RWJ 26251; Leustatin (TN); RWJ-26251; Cladribine [USAN:INN:BAN]; RWJ-26251-000; Cladribine (JAN/USAN/INN); Leustatin, 2-chlorodeoxyadenosine, Cladribine; Adenosine, 2-chloro-2'-deoxy; (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; 2 Chlorodeoxyadenosine; 2'-Deoxy-2-chloroadenosine; 2-CdA; 2-Chloro-2'-deoxy-beta-adenosine; 2-Chloro-2'-deoxyadenosine; 2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine; 2-Chlorodeoxyadenosine; 2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine; 2-chloro-deoxyadenosine

Therapeutic Class

Anticancer Agents

Cross-matching ID

PubChem CID

20279

ChEBI ID

CHEMBL1619

CAS Number

CAS 4291-63-8

TTD Drug ID

D05GJW

VARIDT Drug ID

DR00087

INTEDE Drug ID

DR1918

ACDINA Drug ID

D00951

General Information of Drug (ID: DM3JDRP)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
p53 signaling pathway	2.36	0.00e+0	63/73 (86.3%)	CDKN1A;FAS;DDB2;...
DNA replication	2.05	0.00e+0	34/36 (94.44%)	POLD4;RFC4;RFC5;...
Melanoma	2.03	0.00e+0	68/72 (94.44%)	CDKN1A;DDB2;GADD45A;...
Small cell lung cancer	2.03	0.00e+0	90/92 (97.83%)	CDKN1A;DDB2;GADD45A;...
Amino sugar and nucleotide sugar metabolism	2.01	0.00e+0	38/48 (79.17%)	CYB5R1;NAGK;GALE;...
Glutathione metabolism	2.00	0.00e+0	43/57 (75.44%)	GPX3;GSTM3;RRM2;...
Arachidonic acid metabolism	1.97	0.00e+0	48/61 (78.69%)	AKR1C3;GPX3;ALOX5;...
Nucleotide excision repair	1.96	0.00e+0	40/47 (85.11%)	DDB2;POLD4;RFC4;...
Fructose and mannose metabolism	1.94	0.00e+0	30/33 (90.91%)	AKR1B1;AKR1B10;TIGAR;...
Type I diabetes mellitus	1.94	0.00e+0	38/43 (88.37%)	FAS;HLA-DMB;HLA-B;...
Collecting duct acid secretion	1.91	0.00e+0	22/27 (81.48%)	ATP6V1D;CA2;ATP6V1E1;...
Rheumatoid arthritis	1.89	3.24e-3	78/93 (83.87%)	ATP6V1D;CTSK;IL18;...
Allograft rejection	1.88	2.99e-3	32/38 (84.21%)	FAS;CD40;HLA-DMB;...
Glioma	1.86	7.40e-3	67/75 (89.33%)	CDKN1A;DDB2;GADD45A;...
Mismatch repair	1.85	8.63e-3	22/23 (95.65%)	POLD4;RFC4;RFC5;...
Folate biosynthesis	1.85	9.71e-3	23/26 (88.46%)	AKR1C3;GCH1;AKR1B1;...
Toxoplasmosis	1.84	9.14e-3	103/112 (91.96%)	HSPA2;CD40;PPIF;...
Epstein-Barr virus infection	1.83	9.35e-3	189/202 (93.56%)	CDKN1A;FAS;DDB2;...
Sphingolipid metabolism	1.82	1.09e-2	32/49 (65.31%)	PSAP;GALC;SPHK1;...
TNF signaling pathway	1.81	1.17e-2	103/112 (91.96%)	FAS;CXCL10;JUNB;...
Vibrio cholerae infection	1.81	1.11e-2	44/50 (88%)	ATP6V1D;TJP2;PRKACB;...
Viral myocarditis	1.81	1.12e-2	53/60 (88.33%)	CD40;CAV1;HLA-DMB;...
Apoptosis	1.80	1.18e-2	126/168 (75%)	FAS;GADD45A;CTSK;...
Influenza A	1.72	2.32e-2	156/172 (90.7%)	FAS;MX1;OAS1;...
Other glycan degradation	1.72	2.28e-2	13/18 (72.22%)	MAN2B1;HEXA;HEXB;...
Lysosome	1.71	2.29e-2	115/128 (89.84%)	CTSK;CLTB;CTSV;...
Viral protein interaction with cytokine and cytokine re...	1.70	2.83e-2	84/100 (84%)	CXCL10;TNFRSF10B;IL18;...
Graft-versus-host disease	1.69	2.82e-2	32/42 (76.19%)	FAS;HLA-DMB;HLA-B;...
Regulation of lipolysis in adipocytes	1.67	2.95e-2	52/55 (94.55%)	FABP4;PTGS2;PTGER3;...
Amoebiasis	1.66	3.45e-2	99/102 (97.06%)	CXCL2;PRKACB;ARG2;...
Thiamine metabolism	-1.63	4.38e-2	12/15 (80%)	AK2;AK4;AK1;...
Ribosome	-1.67	3.47e-2	113/158 (71.52%)	MRPL23;RPS3A;RPS24;...
Aminoacyl-tRNA biosynthesis	-1.77	1.64e-2	15/66 (22.73%)	GATC;CARS2;NARS2;...
Ribosome biogenesis in eukaryotes	-1.81	1.40e-2	52/108 (48.15%)	NXT2;GNL3L;POP1;...
Protein export	-1.86	9.35e-3	17/23 (73.91%)	SEC11A;SRPRA;SRP72;...
RNA transport	-1.88	1.25e-2	128/186 (68.82%)	NCBP2;NUP88;POP5;...
mRNA surveillance pathway	-2.00	4.67e-3	71/98 (72.45%)	NCBP1;NCBP2;HBS1L;...
Spliceosome	-2.80	0.00e+0	101/150 (67.33%)	SMNDC1;DHX15;SF3B4;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	0.12uM - 10uM	6H, 24H, 48H

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H, 48H

MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H, 48H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H

VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H